Appendix F.

Table S4. Treatment-emergent serious adverse events reported as related to study treatment, no (%)

	CT-P13 3 mg/kg (N=301)			INX 3 mg/kg (N=301)		
N (%)	**Mild**	**Moderate**	**Severe**	**Mild**	**Moderate**	**Severe**
Neutropenia			1 (0.3)			
Vestibular disorder			1 (0.3)			
Infusion-related reaction		2 (0.7)	2 (0.7)	2 (0.7)	1 (0.3)	1 (0.3)
Hepatitis toxic			1 (0.3)			
Appendicitis						1 (0.3)
Arthritis infective						1 (0.3)
Disseminated TB		1 (0.3)	1 (0.3)			
Pulmonary TB		1 (0.3)				
Herpes zoster						1 (0.3)
Lobar pneumonia	1 (0.3)					
Pneumonia		1 (0.3)				
Wound infection staphylococcal		1 (0.3)				
Musculoskeletal chest pain			1 (0.3)			

Flare in RA activity			1 (0.3)			
Breast cancer						1 (0.3)
Ovarian cancer metastatic						1 (0.3)
Renal neoplasm	1 (0.3)					
Cerebrovascular disorder			1 (0.3)			
Endometrial hyperplasia		1 (0.3)				
Metrorrhagia					1 (0.3)	
Thrombophlebitis			1 (0.3)			

Active TB was reported for three patients and none (0 patients) in the CT-P13 and INX treatment groups, respectively. Latent TB was observed in 13 patients receiving CT-P13 and 14 patients in INX.

The number of patients who were reported to be seroconverted to positive after the study drug exposure with negative results at screening from IGRA test was similar in the CT-P13 (30 patients) and INX treatment groups (28 patients).The three patients with active TB at screening, had negative IGRA results and prophylactic TB medication was not given to them. These patients were from Philippines, Mexico and Poland respectively, and future follow-up on social environment seems to be required.